Bullous autoimmune skin diseases (II): Therapy;Bullöse autoimmundermatosen (11): Therapie

JDDG - Journal of the German Society of Dermatology

Volumn 2, Issue 9, 2004, Pages 774-793

  Goebeler, Matthias ^a   Sitaru, Cassian ^b   Zillikens, Detlef ^b  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; AZATHIOPRINE; CD20 ANTIBODY; CHLORAMBUCIL; CLOBETASOL PROPIONATE; COLCHICINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYCLOSPORIN A; DAPSONE; DEXAMETHASONE; DOXYCYCLINE; ERYTHROMYCIN; ETRETIN; GLUCOCORTICOID; GOLD; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; METHYLPREDNISOLONE; MINOCYCLINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NICOTINAMIDE; PROTEIN A; RITUXIMAB; SULFONAMIDE; TETRACYCLINE; THIOPURINE METHYLTRANSFERASE; UNINDEXED DRUG; CORTICOSTEROID; DERMATOLOGICAL AGENT; IMMUNOLOGIC FACTOR;

ALLERGIC REACTION; ALOPECIA; AMENORRHEA; ANEMIA; APHERESIS; AUTOIMMUNE DISEASE; AZOOSPERMIA; BONE MARROW SUPPRESSION; BULLOUS SKIN DISEASE; CATARACT; DRUG PULSE THERAPY; DUODENUM ULCER; ELECTROLYTE DISTURBANCE; GASTROINTESTINAL SYMPTOM; GERMANY; GINGIVA HYPERPLASIA; HEMOLYSIS; HEMORRHAGIC CYSTITIS; HUMAN; HYPERPIGMENTATION; HYPERSENSITIVITY REACTION; HYPERTENSION; HYPERTRICHOSIS; IMMUNOADSORPTION; INFECTION; LIVER TOXICITY; LYMPHOCYTOPENIA; METHEMOGLOBINEMIA; MUCOSA INFLAMMATION; MYALGIA; MYOPATHY; NEPHROTOXICITY; NEUTROPENIA; OSTEOPOROSIS; PLASMAPHERESIS; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA; THROMBOSIS; ARTICLE; CLINICAL PRACTICE; PRACTICE GUIDELINE; TREATMENT OUTCOME;

ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS; AUTOIMMUNE DISEASES; DERMATOLOGIC AGENTS; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; SKIN DISEASES, VESICULOBULLOUS; TREATMENT OUTCOME;

EID: 4544290383     PISSN: 16100379     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1439-0353.2004.04517.x     Document Type: Review

References (17)

1. Guyatt GH, Cook DJ, Sackett DL, Eckman M, Pauker S. Grades of recommendation for antithrombotic agents. Chest 1998; 114: 441S-444S.
2. Khumalo NP, Murrell DF, Wojnarowska F, Kirtschig G. A systematic review of treatments for bullous pemphigoid. Arch Dermatol 2002; 138: 385-389.
3. Khumalo N, Kirtschig G, Middleton P, Hollis S, Wojnarowska F, Murrell D. Interventions for bullous pemphigoid. The Cochrane Library 2004; 4.
4. Wojnarowska F, Kirtschig G, Highet AS, Venning VA, Khumalo NP. Guidelines for the managmement of bullous pemphigoid. Brit J Dermatol 2002; 147: 214-221.
5. Ahmed AR, Dahl MV, Group. ftCD. Consensus statement for the use of intravenous immunoglobulin therapy in the treatment of autoimmune mucocutaneous blistering diseases. Arch Dermatol 2003; 139: 1051-1059.
6. Wojnarowska F, Kirtschig G, Khumalo N. Treatment of subepidermal immunobullous disease. Clin Dermatol 2001; 19: 768-777.
7. Kirtschig G, Murell D, Wojnarowska F, Khumalo N. Interventions for mucous membrane pemphigoid/cicatricial pemphigoid and epidermolysis bullosa acquisita. Arch Dermatol 2002; 138: 380-384.
8. Kirtschig G, Murrel D, Wojnarowska F, Khumalo N. Interventions for mucous membrane pemphigoid and epidermolysis bullosa acquisita. The Cochrane Library 2004; 1.
9. Chan LS, Ahmed AR, Anhalt GJ, et al. The first international consensus on mucous membrane pemphigoid. Definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. Arch Dermatol 2002; 138: 370-379.
10. Reunala TL. Dermatitis herpetiformis. Clinics Dermatol 2001; 19: 728-736.
11. Nicolas MEO, Krause PK, Gibson LE, Murray JA. Dermatitis herpetiformis. Int J Dermatol 2003; 42: 588-600.
12. Fry L. Dermatitis herpetiformis: problems, progress and prospects. Eur J Dermatol 2002; 12: 523-531.
13. Tóth GG, Jonkman MF. Therapy of pemphigus. Clin Dermatol 2001; 19: 761-767.
14. Fellner MJ, Sapadin AN. Current therapy of pemphigus vulgaris. Mount Sinai J Med 2001; 68: 268-278.
15. Harman KE, Albert S, Black MM. Guidelines for the management of pemphigus vulgaris. Brit J Dermatol 2003; 149: 926-937.
16. Kitajima Y. Current and prospective understanding of clinical classification, pathomechanisms and therapy in pemphigus. Arch Dermatol Res 2003; 295: S17-S23.
17. Robinson ND, Hashimoto T, Amagai M, Chan LS. The new pemphigus variants. J Am Acad Dermatol 1999; 40: 649-671.